Literature DB >> 19623100

Irritable bowel syndrome subtypes defined by Rome II and Rome III criteria are similar.

Spencer D Dorn1, Carolyn B Morris, Yuming Hu, Brenda B Toner, Nicholas Diamant, William E Whitehead, Shrikant I Bangdiwala, Douglas A Drossman.   

Abstract

BACKGROUND: The implications of the Rome III recommendations to change the irritable bowel syndrome (IBS) subtype criteria for stool pattern are unknown. AIM: (1) Determine the level of agreement between Rome II and Rome III subtypes and (2) compare the behaviors of Rome II and Rome III subtypes over time.
METHODS: Female patients (n=148) with Rome II defined IBS were prospectively tracked over 5 consecutive 3-month periods. At baseline, bowel habit reports on questionnaires were used to subclassify patients into Rome II and Rome III subtypes. Over the subsequent 15 months, bowel habit reports on diary cards were used to subclassify patients based on previously derived surrogate criteria into Rome II and Rome III IBS subtypes.
RESULTS: The level of agreement between Rome II and Rome III subtype assignments was quite high (86.5%; kappa 0.79). The behavior of Rome II and Rome III subtypes over time was also similar in terms of subtype prevalence, subtype stability, and the proportion of subjects who met criteria for alternating irritable bowel syndrome.
CONCLUSIONS: Rome II and Rome III IBS subtypes are in high agreement and behave similarly over time. Therefore, studies that used Rome II subtype criteria and studies that will use Rome III criteria will define comparable populations.

Entities:  

Mesh:

Year:  2009        PMID: 19623100     DOI: 10.1097/MCG.0b013e31815bd749

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  23 in total

1.  Characterization of symptoms in irritable bowel syndrome with mixed bowel habit pattern.

Authors:  A M Su; W Shih; A P Presson; L Chang
Journal:  Neurogastroenterol Motil       Date:  2013-08-29       Impact factor: 3.598

2.  IBS patients show frequent fluctuations between loose/watery and hard/lumpy stools: implications for treatment.

Authors:  Olafur S Palsson; Jeffrey S Baggish; Marsha J Turner; William E Whitehead
Journal:  Am J Gastroenterol       Date:  2011-11-08       Impact factor: 10.864

3.  High-sensitive C-Reactive Protein as a Marker for Inflammation in Irritable Bowel Syndrome.

Authors:  Keren Hod; Tamar Ringel-Kulka; Christopher F Martin; Nitsan Maharshak; Yehuda Ringel
Journal:  J Clin Gastroenterol       Date:  2016-03       Impact factor: 3.062

4.  Bloating in Irritable Bowel Syndrome Is Associated with Symptoms Severity, Psychological Factors, and Comorbidities.

Authors:  Keren Hod; Yehuda Ringel; Miranda A L van Tilburg; Tamar Ringel-Kulka
Journal:  Dig Dis Sci       Date:  2018-12-18       Impact factor: 3.199

5.  Questionnaire on Irritable Bowel Syndrome and Symptom Management Among Endurance Athletes Is Valid and Reliable.

Authors:  Lauren A Killian; Karen M Chapman-Novakofski; Soo-Yeun Lee
Journal:  Dig Dis Sci       Date:  2018-09-19       Impact factor: 3.199

6.  Blastocystis subtypes isolated from irritable bowel syndrome patients and co-infection with Helicobacter pylori.

Authors:  Ayman A El-Badry; Wegdan M Abd El Wahab; Doaa A Hamdy; Alaa Aboud
Journal:  Parasitol Res       Date:  2017-11-14       Impact factor: 2.289

Review 7.  5-Hydroxytryptamine (serotonin) in the gastrointestinal tract.

Authors:  Michael D Gershon
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2013-02       Impact factor: 3.243

8.  Current insights in to the pathophysiology of Irritable Bowel Syndrome.

Authors:  Theodoros Karantanos; Theofano Markoutsaki; Maria Gazouli; Nicholas P Anagnou; Dimitrios G Karamanolis
Journal:  Gut Pathog       Date:  2010-05-13       Impact factor: 4.181

9.  Prevalence and risk factors of irritable bowel syndrome in Asia.

Authors:  Oh Young Lee
Journal:  J Neurogastroenterol Motil       Date:  2010-01-31       Impact factor: 4.924

10.  The current prevalence of irritable bowel syndrome in Asia.

Authors:  Full-Young Chang; Ching-Liang Lu; Tseng-Shing Chen
Journal:  J Neurogastroenterol Motil       Date:  2010-10-30       Impact factor: 4.924

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.